The second quarter of 2026 brought another wave of FDA activity, with new medication approvals, expanded indications, and regulatory updates that are shaping patient care. With new options entering obesity care, hypertension, infectious disease, oncology, HIV treatment, thyroid eye disease, and other specialty categories, staying informed is essential for pharmacy teams.
For community pharmacies, the quarter was especially notable because several approvals involve oral or self-managed therapies that may move quickly into everyday dispensing workflows. In this quarter’s roundup, we’ll highlight the FDA developments most relevant to community pharmacists and what they mean for your practice.
Notable FDA indication expansions in Q1 2026
While novel drug approvals continued throughout the quarter, several expanded indications for existing therapies are likely to have an even greater impact on community pharmacy practice. These changes can affect patient eligibility, insurance requirements, counseling needs, and the number of patients who may receive one of these medications.
Tzield
How do you pronounce Tzield? TEZ-yeeld
Expanded use: Broader use in pediatric type 1 diabetes, including younger children at risk of progressing to stage 3 disease and certain children and adolescents recently diagnosed with stage 3 type 1 diabetes.
What changed: The label expanded beyond the original population of patients age 8 and older with stage 2 type 1 diabetes. During Q2, FDA actions broadened access to younger patients and added a role after a recent stage 3 diagnosis for eligible patients ages 8 to 17.
Why it matters for community pharmacies: Although Tzield is an infusion therapy, families may ask community pharmacists about eligibility, safety warnings, vaccine timing, infection risk, and how treatment relates to ongoing insulin therapy. Pharmacists can reinforce that Tzield does not replace insulin for patients with stage 3 diabetes and requires close coordination with the treating specialist. Continued expansion of specialty therapies into broader patient groups Q2 continued a larger trend of specialty medications moving into earlier treatment stages, younger age groups, and more specific biomarker-defined populations.
Linzess
How do you pronounce Linzess? lin-ZESS
Expanded use: Treatment of functional constipation in pediatric patients 2 years of age and older, expanding use to children ages 2 to 5 years.
What changed: The FDA expanded the indication to include children 2 to 5 years of age with functional constipation, making Linzess the first FDA-approved prescription treatment available for this younger pediatric population.
Why it matters: Community pharmacists are likely to receive questions from parents and caregivers about when Linzess is appropriate, how to administer it, and what side effects to expect. Pharmacists can reinforce proper administration (taking the medication on an empty stomach at least 30 minutes before a meal) and counsel caregivers about the most common adverse effect, diarrhea, while reminding them to contact the child’s healthcare provider if severe diarrhea occurs.
Afrezza
How do you pronounce Afrezza? ah-FREZ-uh
Expanded use: Rapid-acting inhaled insulin for improving glycemic control in pediatric patients 6 years of age and older with type 1 or type 2 diabetes. Previously, Afrezza was approved only for adults with diabetes.
What changed: During Q2 2026, the FDA expanded the indication to include children and adolescents ages 6 years and older, making Afrezza the first and only inhaled mealtime insulin approved for pediatric patients with diabetes.
Why it matters for community pharmacies: Community pharmacists may receive questions about how Afrezza compares with injectable mealtime insulin, and who is eligible to use it. Pharmacists can reinforce that Afrezza is taken at the beginning of meals, must be used with a long-acting (basal) insulin in patients with type 1 diabetes, and is not appropriate for patients with asthma, COPD, or other chronic lung disease because of the risk of bronchospasm. Pharmacists can also remind patients that lung function testing is required before starting therapy and periodically during treatment.
Ebglyss
How do you pronounce Ebglyss? EHB-gliss
Expanded use: Less frequent maintenance dosing for adults and pediatric patients 12 years of age and older (weighing at least 40 kg) with moderate-to-severe atopic dermatitis (eczema) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
What changed: During Q2 2026, the FDA approved a new maintenance dosing option of 250 mg every eight weeks for patients who achieve an adequate clinical response after the initial treatment period. Previously, maintenance dosing was every four weeks. The new schedule allows eligible patients to receive as few as six maintenance injections per year.
Why it matters for community pharmacies: Community pharmacists may receive more questions about how the new dosing schedule works, when patients may be eligible to transition to less frequent injections, and the importance of staying on therapy. Pharmacists can reinforce that not all patients will qualify for the every-eight-week schedule, review proper injection storage and administration, counsel on common adverse effects such as conjunctivitis and injection-site reactions, and remind patients to avoid live vaccines while receiving treatment.
Fasenra
How do you pronounce Fasenra? fa-SEN-rah
Expanded use: Treatment of hypereosinophilic syndrome (HES) in adult and pediatric patients 12 years of age and older without an identifiable non-hematologic secondary cause.
What changed: During Q2 2026, the FDA approved Fasenra for the treatment of hypereosinophilic syndrome (HES) in patients 12 years of age and older. This is the first FDA-approved indication for Fasenra in HES and provides a new treatment option for patients living with this rare eosinophilic disorder.
Why it matters for community pharmacies: Although Fasenra is typically prescribed and managed by specialists, community pharmacists may receive questions about the new indication, injection schedule, potential side effects, and insurance coverage. Pharmacists can counsel patients on the importance of continuing prescribed maintenance therapies, recognizing signs of hypersensitivity reactions, and understanding that Fasenra is used to help control eosinophilic inflammation but is not intended for the treatment of acute asthma symptoms or sudden eosinophilic flares. Community pharmacists also play an important role in supporting adherence and coordinating care with specialists.
Tips for community pharmacies with these expanded indications:
- As more medications receive expanded indications, community pharmacies can stay ahead by:
- Educating pharmacy teams on expanded treatment options to better support patient counseling.
- Anticipating insurance coverage changes and prior authorization requirements.
- Using these therapies as opportunities to reinforce adherence, monitoring, and disease-state education.
New FDA drug approvals in Q2 2026
While expanded indications remained a major focus this quarter, several newly approved therapies also stood out for their potential impact on community pharmacy. progress in chronic disease care, giving patients more treatment options and introducing new approaches to therapy.
Foundayo
Approval date: April 1, 2026
How do you pronounce Foundayo? fown-DAY-oh
Indication: Chronic weight management, in combination with a reduced-calorie diet and increased physical activity, in adults with obesity or overweight with at least one weight-related comorbidity.
What makes it notable: The first FDA-approved oral, small-molecule GLP-1 receptor agonist for chronic weight management. Unlike injectable GLP-1 therapies, Foundayo offers a once-daily oral option and does not require fasting or food-and-water restrictions, which may improve convenience for some patients.
Why it matters for pharmacies: This is likely one of the most operationally significant Q2 approvals for community pharmacies. Pharmacy teams should prepare for high patient interest, questions about dose escalation and gastrointestinal side effects, insurance coverage and prior authorizations, and comparisons with injectable GLP-1 therapies. Pharmacists will also play an important role in counseling patients on adherence and lifestyle modifications to support long-term weight management.
Idvynso
Approval date: April 20, 2026
How do you pronounce Idvynso? id-VIN-so
Indication: A complete, once-daily oral regimen for adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen, with no history of treatment failure and no known resistance to doravirine.
What makes it notable: Combines doravirine and islatravir into a once-daily, complete HIV treatment regimen for eligible adults, providing an additional maintenance treatment option for patients who are already virologically suppressed.
Why it matters for pharmacies: As HIV treatment continues to evolve, community pharmacists play an important role in supporting adherence, screening for drug interactions, and counseling patients who transition to new antiretroviral regimens.
Baxfendy
Approval date: May 2026
How do you pronounce Baxfendy? bax-FEN-dee
Indication: Treatment of hypertension, in combination with other antihypertensive medications, to lower blood pressure in adults whose blood pressure is not adequately controlled on other agents.
What makes it notable: Baxfendy (baxdrostat) is a first-in-class aldosterone synthase inhibitor, offering a new approach to lowering blood pressure by targeting aldosterone production.
Why it matters for pharmacies: Hypertension remains one of the most common chronic conditions managed in community pharmacy. Pharmacists can support patients starting Baxfendy by reinforcing adherence, reviewing concomitant antihypertensive therapy, and counseling patients on the importance of routine monitoring for potassium and sodium levels, as the medication may increase the risk of hyperkalemia and hyponatremia.
Veppanu
Approval date: May 2026
How do you pronounce Veppanu? veh-PAN-you
Indication: Treatment of adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
What makes it notable: Veppanu (vepdegestrant) is the first FDA-approved PROTAC (proteolysis-targeting chimera) therapy, providing a targeted oral endocrine treatment option for patients with ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Why it matters for pharmacies: Although many patients will receive Veppanu through specialty pharmacy channels, community pharmacists should be prepared to answer questions about oral oncology medications, review potential drug interactions, reinforce adherence, and counsel patients on common adverse effects and supportive care needs.
Xocova
Approval date: May 29, 2026.
How do you pronounce Xocova: ZOH-koh-vah
Indication: Post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19.
What makes it notable: The first and only FDA-approved oral antiviral indicated to help prevent COVID-19 after a known exposure. Treatment should be started as soon as possible and within 72 hours of exposure.
Why it matters for pharmacies: This approval may generate time-sensitive prescriptions, as treatment must begin within 72 hours of exposure. Community pharmacists should be prepared to confirm patient eligibility, screen for significant drug interactions, counsel patients on the five-day dosing regimen, and reinforce that Xocova is intended for post-exposure prevention and is not a substitute for recommended COVID-19 vaccination or other preventive measures.
Key trends across new approvals
Several themes emerged from Q2 2026 FDA approvals:
- Continued innovation in chronic disease management, with new treatment options for HIV, obesity, hypertension, and advanced breast cancer.
- Growth in first-in-class and novel therapies, including Baxfendy, the first aldosterone synthase inhibitor for hypertension, and Veppanu, the first FDA-approved PROTAC therapy for breast cancer.
- More convenient treatment approaches, such as once-daily oral therapies that may help support adherence and simplify long-term disease management.
- Increasing opportunities for pharmacist counseling, particularly as patients transition to new maintenance therapies, specialty medications, and targeted treatments.
For community pharmacists, not every newly approved medication will become a high-volume prescription but each represents an opportunity to stay informed, answer patient questions with confidence, and support evolving standards of care.
Other FDA updates & regulatory trends
Beyond new drug approvals and expanded indications, several broader FDA developments in Q2 are worth noting. While these updates may not always generate headlines, they reflect larger shifts in medication access, safety oversight, and pharmacy operations.
GLP-1 landscape shifts from shortage response to access management
As GLP-1 medication availability and access evolved during Q2, pharmacies played an important role in helping patients navigate the differences between FDA-approved therapies and compounded products, including questions about coverage, affordability, and continuity of care.
The FDA continued clarifying that compounded versions of GLP-1 medications are not substitutes for FDA-approved therapies and reinforced requirements around when compounding may be appropriate.
What this means for pharmacies:
Community pharmacists may see more patients needing guidance on:
- Transitioning from compounded to FDA-approved therapies
- Insurance coverage challenges
- Manufacturer assistance programs
- Managing expectations around availability and cost
As demand remains high, pharmacists will continue serving as a key resource for accurate medication information.
Growing concerns around unapproved and counterfeit medications
With increasing demand for high-cost specialty and weight-loss therapies, the FDA continued emphasizing the risks associated with purchasing medications through unverified online sources.
What this means for pharmacies:
Pharmacists should be prepared to answer questions from patients who encounter online medication offers, especially around:
- Product authenticity
- Safety concerns
- Differences between approved and unapproved therapies
Trusted pharmacy relationships become even more valuable as patients navigate an increasingly complex medication marketplace.
FDA continues strengthening drug shortage response efforts
Drug shortages remained an ongoing challenge in Q2, with the FDA continuing efforts to improve supply chain visibility, increase manufacturing resilience, and reduce future disruptions.
What this means for pharmacies:
Shortage management continues to be a daily operational reality. Pharmacy teams should maintain processes for:
- Monitoring inventory changes
- Communicating delays
- Coordinating alternatives
- Supporting patients through therapy interruptions
- Supporting appropriate medication use
Increased focus on healthcare misinformation and digital medication claims
As patients increasingly rely on online sources for medication information, the FDA continued monitoring misleading claims and promotional practices surrounding prescription therapies.
What this means for pharmacies:
Community pharmacists are increasingly becoming the trusted source for:
- Clarifying online medication claims
- Explaining treatment options
- Helping patients make informed decisions
Bringing it all together
Q2 highlighted a continued evolution in the FDA’s priorities:
- Managing the transition of high-demand medications from shortage response to long-term access
- Increasing oversight of online medication markets
- Strengthening drug safety monitoring
- Addressing ongoing supply chain challenges
For community pharmacies, the takeaway is clear: regulatory awareness is becoming an essential part of patient care. The role of the pharmacist extends beyond dispensing medications – it includes helping patients understand a changing healthcare landscape and making informed decisions about their treatment.
Want more resources for clinical and operational insights?
Join our email list for how-to guides, toolkits with ready-made marketing materials, and newsletters full of more blogs like these.
ABOUT THE AUTHOR
Michelle Barney, PharmD
Clinical Solutions Manager, Lumistry
Michelle Barney is a Clinical Solutions Manager at Lumistry, where she brings the practicing pharmacist’s perspective into the creation and evolution of pharmacy technology solutions. A clinical pharmacist by training, Michelle has built her career across retail pharmacy and health technology, including serving as Vice President of Clinical Operations at VUCA Health prior to its acquisition by Lumistry. She has held leadership roles spanning clinical operations, product, and marketing, and brings firsthand experience managing pharmacy teams and workflows. In her current role, Michelle partners closely with cross-functional teams to ensure Lumistry’s products are rooted in real-world pharmacy needs—helping pharmacies work more efficiently, confidently, and effectively in their day-to-day practice.
